Humana Inc. $HUM Shares Acquired by Dimensional Fund Advisors LP

Key Points

• Dimensional Fund Advisors LP increased its stake in Humana Inc. by 4.3%, holding over 1.1 million shares worth approximately $292 million at the end of the recent reporting period.
• Analysts have mixed views on Humana's stock, with target price reductions from multiple firms, while others like Oppenheimer have raised their target price.
• Humana's recent quarterly earnings showed an EPS miss at $6.27 compared to estimates, though revenue grew by 9.6% year-over-year.

Dimensional Fund Advisors LP boosted its position in Humana Inc. (NYSE:HUM - Free Report) by 4.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,105,364 shares of the insurance provider's stock after acquiring an additional 45,627 shares during the quarter. Dimensional Fund Advisors LP owned 0.92% of Humana worth $292,474,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in HUM. Cary Street Partners Investment Advisory LLC raised its holdings in Humana by 63.9% in the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock valued at $31,000 after acquiring an additional 46 shares in the last quarter. Riverview Trust Co acquired a new stake in Humana during the first quarter worth approximately $34,000. Garde Capital Inc. acquired a new stake in Humana during the first quarter worth approximately $36,000. Zions Bancorporation National Association UT acquired a new stake in Humana during the first quarter worth approximately $37,000. Finally, Transce3nd LLC acquired a new stake in Humana during the fourth quarter worth approximately $38,000. Institutional investors and hedge funds own 92.38% of the company's stock.

Humana Price Performance

Shares of NYSE HUM traded up $1.8540 during midday trading on Wednesday, hitting $290.1040. The company had a trading volume of 1,247,722 shares, compared to its average volume of 1,729,720. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69. Humana Inc. has a twelve month low of $206.87 and a twelve month high of $382.72. The business has a 50-day simple moving average of $244.92 and a two-hundred day simple moving average of $253.44. The firm has a market capitalization of $34.89 billion, a price-to-earnings ratio of 22.26, a price-to-earnings-growth ratio of 1.69 and a beta of 0.44.

Humana (NYSE:HUM - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 EPS for the quarter, missing the consensus estimate of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The company had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. During the same quarter last year, the business earned $6.96 EPS. The firm's revenue for the quarter was up 9.6% on a year-over-year basis. Humana has set its FY 2025 guidance at 17.000- EPS. Equities research analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Wells Fargo & Company cut their price objective on shares of Humana from $348.00 to $344.00 and set an "overweight" rating on the stock in a report on Thursday, August 14th. Morgan Stanley cut their price objective on shares of Humana from $290.00 to $277.00 and set an "equal weight" rating on the stock in a report on Thursday, July 31st. Barclays set a $275.00 price objective on shares of Humana and gave the stock an "equal weight" rating in a report on Thursday, July 31st. Bank of America cut their price objective on shares of Humana from $320.00 to $260.00 and set a "neutral" rating on the stock in a report on Tuesday, June 17th. Finally, Piper Sandler lowered their target price on shares of Humana from $288.00 to $272.00 and set a "neutral" rating on the stock in a research report on Thursday, July 31st. Seven investment analysts have rated the stock with a Buy rating and sixteen have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $281.43.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.